Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma (PRO-R-IPI)
Observational, Post-authorization, Cross-sectional Study to Evaluate the Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Listed as NCT01369784, this observational or N/A phase trial focuses on Diffuse Large B-cell Lymphoma and remains completed. Sponsored by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, it has been updated 7 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Feb 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Alcorcón, Spain , Badalona, Spain , Barcelona, Spain , Bilbao, Spain , Elda, Spain , Getafe, Spain , Gijón, Spain , Girona, Spain , Granada, Spain and 34 more locations